|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, IDH and TERTp co-occurred in 75% of 1p/19q intact, TP53 wild-type oligodendrogliomas, highlighting the potential of the co-mutations in assisting diagnosis of oligodendrogliomas in tumors with clear cell morphology and non-codeleted 1p/19q status.
|
27556304 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second.
|
29077933 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the aberration profiles of IDH1 and BRAF suggest that the oligodendroglioma arose independent of cerebellar pilocytic astrocytoma.
|
23082883 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In patients with ODG (Group 1), mutant IDH and TERTp did not have prognostic value because these mutations were universally present.
|
28851427 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In recent studies, presence of IDH1 mutation has shown immense prognostic significance in glial tumours including oligodendrogliomas, but its role in neurocytoma pathogenesis remains unexplored.
|
21532524 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel).
|
29186201 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study we searched for FGFR1-ITD by droplet digital PCR (DDPCR™) and for FGFR1 point mutations by HRM-sequencing in a series of formalin-fixed paraffin-embedded (FFPE) LGNTs including 12 DNT, 2 oligodendrogliomas lacking IDH mutation and 1p/19q co- deletion (pediatric-type oligodendrogliomas; PTOs), 3 pediatric diffuse astrocytomas (PDAs), 14 gangliogliomas (GGs) and 5 pilocytic astrocytomas (PAs).
|
27791984 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Most tumors have a missense mutation for IDH1 combined with 1p19q codeletion in oligodendrogliomas or ATRX/TP53 mutations in astrocytomas.
|
29027701 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase enzyme isoforms 1 (IDH1) and 2 (IDH2) have been identified in many adult astrocytomas and oligodendrogliomas.
|
19915484 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been identified in approximately 70-80 % of astrocytomas and oligodendrogliomas of WHO grades II and III, and in secondary glioblastomas.
|
22528790 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase (IDH) genes occur frequently in low-grade astrocytomas and oligodendrogliomas (World Health Organization [WHO] grade II), and in higher-grade gliomas (WHO grades III and IV) that arise after malignant progression of low-grade tumors.
|
23909061 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas.
|
19996293 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Next-generation molecular biology technologies have recently identified recurrent CIC and FUBP1 point mutations in 1p/19q codeleted and IDH-mutated oligodendrogliomas.
|
22913971 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Non-canonical IDH mutations were identified in 13/52 (25.0%) grade II gliomas (astrocytomas: 8/31, 25.8%; oligodendrogliomas: 5/21, 23.8%) and in 5/40 (12.5%) grade III gliomas (astrocytomas: 3/25, 12.0%; oligodendrogliomas: 2/15, 13.3%).
|
28748342 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred twenty-six tumors could be classified: 20 as type II (IDH mutation [mut], "astrocytoma"), 49 as type I (1p/19q codeletion, "oligodendroglioma"), 55 as type III (7+/10q- or TERTmut and 1p/19q intact, "glioblastoma"), and 2 as childhood glioblastoma (H3F3Amut), leaving 7 unclassified (total 91% classified).
|
26354927 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups.
|
26493382 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patient KK was a 68-yr-old female who was found to have a large, left-sided insular mass that was shown to be an oligodendroglioma WHO grade II, positive for codeletion 1p/19q and IDH1 mutant on biopsy.
|
31058967 |
2020 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, isocitrate dehydrogenase 1 (IDH1) mutations have been identified as a very early and frequent genetic alteration in the pathway to secondary glioblastomas as well as that in oligodendroglial tumors, providing the first evidence that low-grade astrocytomas and oligodendrogliomas may share common cells of origin.
|
19737147 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Secondly, when analyzed in molecular subgroups, we were similarly unable to detect a significant PFS or OS benefit in IDH MT/codel subgroup (N = 269; HR 1.47; 95% CI 0.92-2.34; P = 0.11 and HR 1.54; 95% CI 0.78-3.05; P = 0.21, respectively), oligodendroglioma with IDH MT/codel subgroup (N = 233; HR 1.33; 95% CI 0.79-2.21; P = 0.28 and HR 1.16; 95% CI 0.53-2.54; P = 0.70, respectively) or other relevant subgroups.
|
30206763 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several studies on molecular profiling of oligodendrogliomas (OGs) in adults have shown a distinctive genetic pattern characterized by combined deletions of chromosome arms 1p and 19q, O6-methylguanine-methyltransferase (MGMT) methylation, and isocitrate dehydrogenase 1 (IDH1) mutation, which have potential diagnostic, prognostic, and even therapeutic relevance.
|
21937591 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixty-five patients with 2007 histological designations (astrocytomas and oligodendrogliomas), 1p/19q status (+ = intact/- = co-deleted), and IDH1 mutation status (MUT/WT) were included in this study.
|
28547590 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 25th, 50th, 75th, and 90th percentiles of MK and average MK showed significant differences between IDH1/2<sub>wild-type</sub> gliomas, IDH1/2<sub>mutated</sub> gliomas, and oligodendrogliomas with chromosome 1p/19q loss of heterozygosity and IDH1/2<sub>mutation</sub> (p<0.001).
|
28987669 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The oligodendroglioma model presented here is a valuable model for further functional elucidation of the effects of IDH1 mutations on tumor metabolism and may aid in the rational development of novel therapeutic strategies for the large subgroup of gliomas carrying IDH1 mutations.
|
24252742 |
2013 |